Literature DB >> 1534247

Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.

H T Tevaearai1, P L Laurent, L Suardet, J F Eliason, J C Givel, N Odartchenko.   

Abstract

The biological activity of 5'-deoxy-5-fluorouridine (5'-dFUrd) depends upon intracellular enzymatic cleavage by pyrimidine phosphorylase to form 5-fluorouracil (5-FU). Interferon-alpha 2a (IFN-alpha) effect was analysed alone and combined with 5-FU or 5'-dFUrd, on proliferation inhibition of eight human colorectal cancer cell lines. The toxicity of 5-FU was enhanced by IFN-alpha in only one line (SW-480). In contrast, interactive enhancement of IFN-alpha was observed with 5'-dFUrd in five lines (WiDr, HT-29, 513, SW-480 and Co-115). In each of the lines showing potentiation by IFN/5'dFUrd but not by IFN/5-FU, cytoplasmic pyrimidine phosphorylase activity was increased after 5 days' incubation with IFN-alpha in a dose-dependent manner. Two lines (LISP-1 and SW-620) showed no potentiation of either 5-FU or 5'-dFUrd toxicity by IFN-alpha, and no change in pyrimidine phosphorylase activity. Potentiation of 5'-dFUrd effect by IFN-alpha may thus be explained by an enhancement of its conversion to 5-FU through stimulation of pyrimidine phosphorylase activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534247     DOI: 10.1016/s0959-8049(05)80055-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

Review 1.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

Review 2.  Capecitabine: preclinical pharmacology studies.

Authors:  H Ishitsuka
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; M Ura; A Hino; Y Tanaka; K Wada; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells.

Authors:  Shuhei Sakakibara; Cynthia A Pise-Masison; John N Brady; Giovanna Tosato
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

Review 6.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

Review 7.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.

Authors:  L Griffiths; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.

Authors:  P Kabuubi; J A Loncaster; S E Davidson; R D Hunter; C Kobylecki; I J Stratford; C M L West
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

9.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03

10.  Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; T Ishikawa; T Ohiwa; K Tatsuno; Y Tanaka; H Ishitsuka
Journal:  Jpn J Cancer Res       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.